AKT1 and non-small cell lung carcinoma: This study highlights the potential of 2,3′-dihydroxy-5′-methoxystilbene as a targeted therapeutic candidate for NSCLC, particularly in the H23 and H460 subtypes, through the inhibition of proliferation, clonogenicity, and migration, and induction of apoptosis via the PI3K/AKT signaling pathway.